U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07340138) titled 'Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis' on Jan. 06.
Brief Summary: This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
Study Start Date: May 29, 2026
Study Type: INTERVENTIONAL
Condition:
Primary Myelofibrosis (PMF)
Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Intervention:
DRUG: Pelabresib
125 mg orally once daily (QD) on Days 1-14 of each 21-day cycle
DRUG: Rux...